JP2025507292A - プロテインチロシンホスファターゼ阻害剤およびその使用 - Google Patents

プロテインチロシンホスファターゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP2025507292A
JP2025507292A JP2024546071A JP2024546071A JP2025507292A JP 2025507292 A JP2025507292 A JP 2025507292A JP 2024546071 A JP2024546071 A JP 2024546071A JP 2024546071 A JP2024546071 A JP 2024546071A JP 2025507292 A JP2025507292 A JP 2025507292A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546071A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023150535A5 (https=
JP2025507292A5 (https=
Inventor
ローランド，ジェイソン
ジー． デュロン，セルジオ
Original Assignee
ネリオ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネリオ セラピューティクス，インク． filed Critical ネリオ セラピューティクス，インク．
Publication of JP2025507292A publication Critical patent/JP2025507292A/ja
Publication of JPWO2023150535A5 publication Critical patent/JPWO2023150535A5/ja
Publication of JP2025507292A5 publication Critical patent/JP2025507292A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2024546071A 2022-02-02 2023-02-01 プロテインチロシンホスファターゼ阻害剤およびその使用 Pending JP2025507292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305786P 2022-02-02 2022-02-02
US63/305,786 2022-02-02
PCT/US2023/061727 WO2023150535A1 (en) 2022-02-02 2023-02-01 Protein tyrosine phosphatase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2025507292A true JP2025507292A (ja) 2025-03-18
JPWO2023150535A5 JPWO2023150535A5 (https=) 2026-02-09
JP2025507292A5 JP2025507292A5 (https=) 2026-02-09

Family

ID=87552989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546071A Pending JP2025507292A (ja) 2022-02-02 2023-02-01 プロテインチロシンホスファターゼ阻害剤およびその使用

Country Status (7)

Country Link
US (1) US20250136564A1 (https=)
EP (1) EP4472976A4 (https=)
JP (1) JP2025507292A (https=)
CN (1) CN119137117A (https=)
AR (1) AR128418A1 (https=)
TW (1) TW202337459A (https=)
WO (1) WO2023150535A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506400A (ja) * 2022-02-02 2025-03-11 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
RU2015140066A (ru) * 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
PE20252767A1 (es) * 2019-03-14 2025-12-22 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos
CA3191842A1 (en) * 2020-09-11 2022-03-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
CN117279913A (zh) * 2021-03-11 2023-12-22 金橘生物科技公司 杂环化合物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506400A (ja) * 2022-02-02 2025-03-11 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用

Also Published As

Publication number Publication date
EP4472976A1 (en) 2024-12-11
TW202337459A (zh) 2023-10-01
US20250136564A1 (en) 2025-05-01
AR128418A1 (es) 2024-05-08
EP4472976A4 (en) 2026-03-25
WO2023150535A1 (en) 2023-08-10
CN119137117A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
JP2025505994A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025507292A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025513882A (ja) タンパク質チロシンホスファターゼ阻害剤およびその使用
JP2025506400A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
US20250145624A1 (en) Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US20140142094A1 (en) Kinase inhibitors
US20250188094A1 (en) Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN119630670A (zh) TNFα活性调节剂及其用途
US12103915B2 (en) TEAD inhibitors and methods of uses thereof
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250214990A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
CN121175313A (zh) Nlrp3炎症小体抑制剂及其用途
CN121620514A (zh) 蛋白质酪氨酸磷酸酶降解剂及其用途
CN118974027A (zh) 蛋白质酪氨酸磷酸酶抑制剂及其用途
WO2025201397A1 (en) Tead inhibitors and methods of uses thereof
WO2025232839A1 (en) Nlrp3 inflammasome inhibitors and uses thereof
CN121443601A (zh) 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260130